Acumen Pharmaceuticals (ABOS) Non Operating Income (2020 - 2026)

Acumen Pharmaceuticals (ABOS) has 7 years of Non Operating Income data on file, last reported at $412000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 73.82% year-over-year to $412000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 87.12% YoY), and the FY2025 full-year result was $2.5 million, down 78.64% from the prior year.
• Non Operating Income advanced to $412000.0 in Q1 2026, from $61000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.8 million in Q2 2024 to a low of $61000.0 in Q4 2025.
• A 5-year average of $1.5 million and a median of $1.6 million in 2025 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income jumped 6400.0% in 2022 and plunged 97.52% in 2025, its largest moves.
• Tracing ABOS's Non Operating Income over 5 years: stood at $1.4 million in 2022, then surged by 43.92% to $2.0 million in 2023, then grew by 22.83% to $2.4 million in 2024, then plunged by 97.5% to $61000.0 in 2025, then jumped by 575.41% to $412000.0 in 2026.
• Business Quant data shows ABOS's Non Operating Income at $412000.0 in Q1 2026, $61000.0 in Q4 2025, and $62000.0 in Q3 2025.